ATE78293T1 - Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. - Google Patents

Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.

Info

Publication number
ATE78293T1
ATE78293T1 AT84105841T AT84105841T ATE78293T1 AT E78293 T1 ATE78293 T1 AT E78293T1 AT 84105841 T AT84105841 T AT 84105841T AT 84105841 T AT84105841 T AT 84105841T AT E78293 T1 ATE78293 T1 AT E78293T1
Authority
AT
Austria
Prior art keywords
baculovirus
selected gene
recombinant
expression vector
dna
Prior art date
Application number
AT84105841T
Other languages
English (en)
Inventor
Gale E Smith
Max D Summers
Original Assignee
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/498,858 external-priority patent/US4745051A/en
Application filed by Texas A & M Univ Sys filed Critical Texas A & M Univ Sys
Application granted granted Critical
Publication of ATE78293T1 publication Critical patent/ATE78293T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT84105841T 1983-05-27 1984-05-22 Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. ATE78293T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/498,858 US4745051A (en) 1983-05-27 1983-05-27 Method for producing a recombinant baculovirus expression vector
US60969784A 1984-05-16 1984-05-16
EP84105841A EP0127839B1 (de) 1983-05-27 1984-05-22 Verfahren zur Herstellung eines rekombinanten Baculovirus-Expressionsvektors

Publications (1)

Publication Number Publication Date
ATE78293T1 true ATE78293T1 (de) 1992-08-15

Family

ID=27052974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84105841T ATE78293T1 (de) 1983-05-27 1984-05-22 Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.

Country Status (17)

Country Link
EP (1) EP0127839B1 (de)
JP (2) JPH0779700B2 (de)
KR (1) KR910009203B1 (de)
AT (1) ATE78293T1 (de)
AU (1) AU581174B2 (de)
BR (1) BR8402666A (de)
CA (1) CA1222213A (de)
DE (1) DE3485810T2 (de)
DK (1) DK172401B1 (de)
ES (1) ES8507176A1 (de)
IE (1) IE58011B1 (de)
IL (1) IL71906A (de)
IN (1) IN160416B (de)
MX (1) MX164250B (de)
NO (1) NO173944C (de)
NZ (1) NZ208259A (de)
PH (1) PH25395A (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
JPS619288A (ja) * 1984-06-21 1986-01-16 Dai Ichi Seiyaku Co Ltd ペプチド類の製法
US5004687A (en) * 1985-05-21 1991-04-02 University Of Georgia Research Foundation, Inc. Insect virus vector with broadened host range
GB8521496D0 (en) * 1985-08-29 1985-10-02 Ciba Geigy Ag Repressible yeast promoters
FR2593519B1 (fr) * 1985-09-25 1994-01-07 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
IL80529A0 (en) * 1985-11-14 1987-02-27 Daiichi Seiyaku Co Method of producing peptides
EP0228036A3 (de) * 1985-12-18 1988-09-07 Microgenesys, Inc. Verfahren zur Herstellung von spezifischen Polypeptiden in virusinfizierten Insektzellen und daraus isolierte Polypeptide
EP0260090A3 (de) * 1986-09-08 1988-07-27 David H.L. Bishop Expression von Hepatitis B-Virusantigenen von rekombinanten Bakulovirusvektoren
US5071748A (en) * 1986-09-09 1991-12-10 Genetics Institute, Inc. Mixed baculovirus compositions and uses thereof
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
EP0349594A4 (en) * 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
US5041379A (en) * 1987-03-16 1991-08-20 American Biogenetic Science, Inc. Heliothis expression systems
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
JPH02504103A (ja) * 1987-06-30 1990-11-29 ジ・アップジョン・カンパニー 減少したｏ‐連結グリコシレーションを有するウイルスタンパク質
WO1989001037A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5372943A (en) * 1987-07-24 1994-12-13 Cetus Corporation Lipid microemulsions for culture media
WO1989001038A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5876962A (en) * 1987-08-12 1999-03-02 Natural Environment Research Council Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
GB8810808D0 (en) * 1988-05-06 1988-06-08 Wellcome Found Vectors
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
FR2631974B1 (fr) * 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
EP0359714B1 (de) * 1988-09-16 1994-01-12 Sandoz Ag Diuretischer Faktor
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor
US5145775A (en) * 1989-02-28 1992-09-08 Research Association For Biotechnology Of Agricultural Chemicals Polyhedrin gene and genetic engineering thereof
GB8910962D0 (en) * 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
FR2664905B1 (fr) * 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
EP0533469A1 (de) * 1991-09-18 1993-03-24 Hong Kong Tech Company Limited Expressionsvektor und diesen enthaltender Seidenwurmtransformant
IT1259042B (it) * 1992-01-27 1996-03-11 Mini Ricerca Scient Tecnolog Preparazione di vettori di espressione per la sintesi del polipeptide chiamato fattore osteogenetico op-1 in cellule eucariotiche di spodoptera frugiperda via infezione con baculovirus ricombinante
ES2048646B1 (es) * 1992-04-15 1994-10-01 Ercros Sa Procedimiento para la obtencion de la proteina vp2 del virus de la peste equina africana (ahsv)
CA2179394A1 (en) * 1993-12-23 1995-06-29 Kostas Iatrou Methods of expressing proteins in insect cells and methods of killing insects
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5952210A (en) * 1994-06-03 1999-09-14 G. D. Searle & Company Nucleic acids and expression vectors encoding human leukotiene C4 synthase
JP2640623B2 (ja) * 1994-06-10 1997-08-13 日本製粉株式会社 ターミナルデオキシヌクレオチジルトランスフェラーゼの製造方法
US5804410A (en) * 1994-07-29 1998-09-08 Teijin Limited Nucleic acid sequence encoding trypsin-like enzyme and process for producing the enzyme
JP2565668B2 (ja) * 1995-01-17 1996-12-18 第一製薬株式会社 ペプチド類の製造用ベクター
FR2732035B1 (fr) * 1995-03-23 1997-05-30 Agronomique Inst Nat Rech Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1998044141A2 (en) * 1997-03-27 1998-10-08 The University Of British Columbia Insect expression vectors
DK1007546T3 (da) 1997-08-27 2009-03-16 Novartis Vaccines & Diagnostic Molekylære mimetika af meningokok-B-epitoper
EP1900818A3 (de) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neissersche Antigene
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261347A3 (de) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
EP1961813B1 (de) 1998-12-16 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Menschliche Cyclin-abhängige Kinase (hPNQALRE)
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CA2383642C (en) 1999-10-14 2014-03-25 Clontech Laboratories, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
EP1226253A2 (de) 1999-10-29 2002-07-31 Chiron S.P.A. Antigene peptide aus neisseria
JP5250168B2 (ja) 2000-01-10 2013-07-31 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 乳癌において差次的に発現される遺伝子
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ATE439372T1 (de) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
EP2168596B1 (de) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
EP1456223B1 (de) 2001-12-19 2009-08-12 The University Of Chicago Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
WO2003099854A2 (en) 2002-05-24 2003-12-04 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
EP1513945A4 (de) 2002-05-24 2008-12-24 Restoragen Inc Verfahren zur universellen enzymatischen herstellung bioaktiver peptide
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
ATE409048T1 (de) 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
PT2380985E (pt) 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
DK2189523T3 (da) 2003-10-14 2012-03-12 Baxter Int VKORC1 (vitamin K-epoxid-tilbageføringspolypeptid), et terapeutisk mål for coumarin og dets derivater
HRP20120315T1 (hr) 2003-11-21 2012-05-31 Nps Pharmaceuticals Proizvodnja peptida 2 nalik glukagonu i analoga
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
ES2390885T3 (es) 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
EP1732944B1 (de) 2004-04-07 2012-09-05 The University of Chicago Monomere, rotfluoreszierende proteine
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
WO2006102243A2 (en) 2005-03-21 2006-09-28 Applera Corporation Alpha ketoamide compounds as cysteine protease inhibitors
JP2008544746A (ja) 2005-05-12 2008-12-11 ザイモジェネティクス， インコーポレイテッド 免疫応答を調節するための組成物および方法
NZ565253A (en) 2005-06-24 2011-06-30 Teijin Pharma Ltd Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
EP1762250A1 (de) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
DE102006058373A1 (de) 2006-12-08 2008-06-12 Evocatal Gmbh (R)-Hydroxynitril-Lyase aus Brassicaceen
DE102007014742A1 (de) 2007-03-23 2008-09-25 Evonik Degussa Gmbh Isoformen der Schweineleber Esterase
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
US8003325B2 (en) 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
NO2337846T3 (de) 2008-09-26 2018-06-16
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
DE102009007272A1 (de) 2009-02-03 2010-08-05 Evocatal Gmbh Alkoholdehydrogenase aus Gluconobacter oxydans und deren Verwendung
EP2292781A1 (de) 2009-08-17 2011-03-09 Genethon Baculovirus-basierte Herstellung von Biopharmazeutika ohne kontaminierende baculovirale Virionen
EP2333074A1 (de) 2009-12-14 2011-06-15 Robert Steinfeld Substanzen und Verfahren zur Behandlung von lyosomalen Speicherkrankheiten
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
WO2012018431A1 (en) * 2010-07-26 2012-02-09 Seven Networks, Inc. Prediction of activity session for mobile network use optimization and user experience enhancement
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
IN2014CN00688A (de) 2011-07-27 2015-04-03 Genethon
EP3770169A1 (de) 2013-09-12 2021-01-27 BioMarin Pharmaceutical Inc. Adeno-assoziierte virusfaktor-viii-vektoren
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
PE20181338A1 (es) 2015-09-24 2018-08-21 Biomarin Pharm Inc Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
RU2761264C2 (ru) 2015-11-12 2021-12-06 Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал Способы лечения мышечной дистрофии
EP3377042A4 (de) 2015-11-16 2019-05-29 The Research Institute at Nationwide Children's Hospital Materialien und verfahren zur behandlung von titinbasierten myopathien und anderen titinopathien
EP3222712A1 (de) 2016-03-22 2017-09-27 Universität zu Köln Alkoholdehydrogenase aus pichia pastoris und ihre verwendung
AU2017301600B2 (en) 2016-07-26 2022-08-04 Biomarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US20200231986A1 (en) 2017-09-29 2020-07-23 Massachusetts Eye And Ear Infirmary Production of adeno-associated viruses in insect cells
AR114350A1 (es) 2018-01-31 2020-08-26 Res Institute At Nationwide Children’S Hospital Terapia genética para la distrofia muscular de cinturas del tipo 2c
CA3099704A1 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
JP2021523198A (ja) 2018-05-14 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド 幼若対象におけるａａｖベクターの安定的発現
WO2020006458A1 (en) 2018-06-29 2020-01-02 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
CA3131390A1 (en) 2019-02-26 2020-09-03 Research Institute Of Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
WO2020232044A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
EP4488287A3 (de) 2019-08-21 2025-03-05 Research Institute at Nationwide Children's Hospital Adeno-assoziierte virusvektorverabreichung von alpha-sarcoglycan und behandlung von muskeldystrophie
KR20220066164A (ko) 2019-09-27 2022-05-23 바이오마린 파머수티컬 인크. 크기 배제 크로마토그래피 및 다각도 광 산란 기술을 사용한 유전자 치료 바이러스 입자의 특성화
AU2020384294A1 (en) 2019-11-14 2022-06-02 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with liver-specific gene therapy vectors
US20230075854A1 (en) 2020-02-10 2023-03-09 Biomarin Pharmaceutical Inc. Virus-free cell cultures
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
US20230407328A1 (en) 2020-11-02 2023-12-21 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
US20240408240A1 (en) 2021-10-01 2024-12-12 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
KR20250108100A (ko) 2022-09-22 2025-07-15 디나코 아게 Aav 유전자 치료법 벡터를 이용한 심근병증의 치료
TW202421788A (zh) 2022-09-22 2024-06-01 美商拜奧馬林製藥公司 用ａａｖ基因療法載體治療致心律不整性心肌病
WO2024151568A1 (en) 2023-01-09 2024-07-18 Biomarin Pharmaceutical Inc. Epigenetic modifiers improve aav gene therapy durability
WO2024238591A2 (en) 2023-05-15 2024-11-21 Biomarin Pharmaceutical Inc. Methods of treating anti-aav seropositive hemophilia patients
WO2025214477A1 (en) 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors

Also Published As

Publication number Publication date
CA1222213A (en) 1987-05-26
JPS6037988A (ja) 1985-02-27
KR840008818A (ko) 1984-12-19
BR8402666A (pt) 1985-05-07
PH25395A (en) 1991-06-03
IN160416B (de) 1987-07-11
EP0127839A2 (de) 1984-12-12
NO173944B (no) 1993-11-15
JP2644447B2 (ja) 1997-08-25
AU2871784A (en) 1984-11-29
NO842094L (no) 1984-11-28
JPH0779700B2 (ja) 1995-08-30
DK257984D0 (da) 1984-05-25
IL71906A0 (en) 1984-09-30
DE3485810D1 (de) 1992-08-20
NZ208259A (en) 1988-01-08
EP0127839B1 (de) 1992-07-15
IE841269L (en) 1984-11-27
DE3485810T2 (de) 1992-12-10
IL71906A (en) 1992-08-18
KR910009203B1 (ko) 1991-11-04
AU581174B2 (en) 1989-02-16
EP0127839A3 (en) 1986-06-25
DK172401B1 (da) 1998-05-18
NO173944C (no) 1994-02-23
ES532825A0 (es) 1985-08-16
JPH0799989A (ja) 1995-04-18
IE58011B1 (en) 1993-06-16
MX164250B (es) 1992-07-27
ES8507176A1 (es) 1985-08-16
DK257984A (da) 1984-11-28

Similar Documents

Publication Publication Date Title
DE3485810D1 (de) Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
KR880014110A (ko) 인체 프로아포지방단백질 a-i의 발현
CA2099841A1 (en) Expression of recombinant proteins in attenuated bacteria
ATE160176T1 (de) Verfahren zur herstellung eines proteins mittels eines durch mehrfachkopieintegrierung eines expressionsvektors transformierten pilzes
DE69231137D1 (de) Verfahren zur Herstellung von Peroxidasen in einem Aspergillusstamm
ATE205253T1 (de) Induzierbare virusresistenz bei pflanzen
KR840005745A (ko) B형 간염비루스 유전자를 삽입한 조환 플라스미드, 이 조환 플라스미드로 전환된 효모 및 b형 간염비루스 표면항원의 제조방법
ATE237693T1 (de) Rekombinante foamy-virus-vektoren zur medizinischen und diagnostischen verwendung und verfahren zur herstellung rekombinanter foamy- virus-vektoren
DE69109298D1 (de) Verfahren zur modifizierung von zell-, gewebe- oder wirts-tropismus eines mikroorganismus, so erhaltene rekombinante mikroorganismen sowie deren verwendung in medizin und tiermedizin.
AU5961596A (en) Method for expression and isolation of biologically active m olecules in urine
SE8105516L (sv) Syntetisk dna och forfarande for framstellning derav
IE863325L (en) Producing polypeptides in virally infected insect cells
ATE100495T1 (de) Rekombinantes marek-krankheitsvirus, verfahren zu seiner herstellung, und vakzine.
DE69224269D1 (de) Biosynthetisches Verfahren zur Herstellung von Protein
CA2037677A1 (en) Process for production of exogenous gene or its product in plant cells
DE3882455D1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
KR880000579A (ko) 베리셀라-죠스터 바이러스의 생산방법
DE3889562D1 (de) Rekombinante Plasmide, die zur Expression von heterologen Proteinen in Bacillus verwendet werden können.
ATE118816T1 (de) Verfahren zur herstellung von acci- restriktionsendonuklease und -methylase.
ATE101647T1 (de) Verfahren zur herstellung von aseirestriktionsendonuklease und -methylase.
RU2001104431A (ru) Способ получения белков в трансформированных дрожжевых клетках
ATE122097T1 (de) Expressionsvektor und verfahren zur regulierbaren herstellung von proteinen in eukaryonten.
KR920012431A (ko) 인간 표피 성장인자의 발현벡터
KR950005990A (ko) 인간 인터류킨-4(human interleukin-4)의 효모에서의 발현

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time